Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker DFTX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Daniel Karlin Chief Medical Officer, Director | DFTX Definium Therapeutics, Inc. | Sale | 10,853 | $36.57 | $396.9K Sale | Form 4 ↗ |
| Sep 25, 2026 | Robert Barrow Chief Executive Officer, Director | DFTX Definium Therapeutics, Inc. | Sale | 31,550 | $36.57 | $1.2M Sale | Form 4 ↗ |
| Sep 25, 2026 | Matthew T. Wiley Chief Commercial Officer | DFTX Definium Therapeutics, Inc. | Sale | 3,097 | $36.57 | $113.3K Sale | Form 4 ↗ |
| Sep 25, 2026 | Mark Sullivan Chief Legal Officer | DFTX Definium Therapeutics, Inc. | Sale | 14,051 | $36.57 | $513.8K Sale | Form 4 ↗ |
| Sep 25, 2026 | Brandi Roberts Chief Financial Officer | DFTX Definium Therapeutics, Inc. | Sale | 3,377 | $36.57 | $123.5K Sale | Form 4 ↗ |
| Sep 3, 2026 | Robert Barrow Chief Executive Officer, Director | DFTX Definium Therapeutics, Inc. | Sale | 19,023 | $37.94 | $721.7K Sale | Form 4 ↗ |
| Jun 25, 2026 | Mark Sullivan Chief Legal Officer | DFTX Definium Therapeutics, Inc. | Sale | 13,008 | $45.03 | $585.8K Sale | Form 4 ↗ |
| Jun 25, 2026 | Daniel Karlin Chief Medical Officer | DFTX Definium Therapeutics, Inc. | Sale | 10,035 | $45.03 | $451.9K Sale | Form 4 ↗ |
| Jun 25, 2026 | Brandi Roberts Chief Financial Officer | DFTX Definium Therapeutics, Inc. | Sale | 3,013 | $45.03 | $135.7K Sale | Form 4 ↗ |
| Jun 25, 2026 | Robert Barrow Chief Executive Officer, Director | DFTX Definium Therapeutics, Inc. | Sale | 29,208 | $45.03 | $1.3M Sale | Form 4 ↗ |
| Jun 25, 2026 | Matthew T. Wiley Chief Commercial Officer | DFTX Definium Therapeutics, Inc. | Sale | 2,867 | $45.03 | $129.1K Sale | Form 4 ↗ |
| Mar 25, 2026 | Daniel Karlin Chief Medical Officer | DFTX Definium Therapeutics, Inc. | Sale | 8,018 | $18.47 | $148.1K Sale | Form 4 ↗ |
| Mar 25, 2026 | Mark Sullivan Chief Legal Officer | DFTX Definium Therapeutics, Inc. | Sale | 10,702 | $18.47 | $197.7K Sale | Form 4 ↗ |
| Mar 25, 2026 | Robert Barrow Chief Executive Officer, Director | DFTX Definium Therapeutics, Inc. | Sale | 24,431 | $18.47 | $451.2K Sale | Form 4 ↗ |
| Dec 26, 2025 | Daniel Karlin Chief Medical Officer | MNMD Definium Therapeutics, Inc. | Sale | 5,600 | $13.15 | $73.6K Sale | Form 4 ↗ |
| Dec 26, 2025 | Robert Barrow Chief Executive Officer, Director | MNMD Definium Therapeutics, Inc. | Sale | 25,791 | $13.15 | $339.2K Sale | Form 4 ↗ |
| Dec 26, 2025 | Mark Sullivan Chief Legal Officer | MNMD Definium Therapeutics, Inc. | Sale | 11,276 | $13.15 | $148.3K Sale | Form 4 ↗ |
| Sep 25, 2025 | Mark Sullivan Chief Legal Officer | MNMD Definium Therapeutics, Inc. | Sale | 11,278 | $9.77 | $110.2K Sale | Form 4 ↗ |
| Sep 25, 2025 | Robert Barrow Chief Executive Officer, Director | MNMD Definium Therapeutics, Inc. | Sale | 25,797 | $9.77 | $252.0K Sale | Form 4 ↗ |
| Sep 25, 2025 | Daniel Karlin Chief Medical Officer | MNMD Definium Therapeutics, Inc. | Sale | 7,704 | $9.77 | $75.3K Sale | Form 4 ↗ |
| Jun 25, 2025 | Mark Sullivan Chief Legal Officer | MNMD Definium Therapeutics, Inc. | Sale | 11,491 | $6.80 | $78.1K Sale | Form 4 ↗ |
| Jun 25, 2025 | Daniel Karlin Chief Medical Officer | MNMD Definium Therapeutics, Inc. | Sale | 7,848 | $6.80 | $53.4K Sale | Form 4 ↗ |
| Jun 25, 2025 | Robert Barrow Chief Executive Officer, Director | MNMD Definium Therapeutics, Inc. | Sale | 26,491 | $6.80 | $180.1K Sale | Form 4 ↗ |
| Mar 25, 2025 | Robert Barrow Chief Executive Officer, Director | MNMD Definium Therapeutics, Inc. | Sale | 21,208 | $6.74 | $142.9K Sale | Form 4 ↗ |
| Mar 25, 2025 | Daniel Karlin Chief Medical Officer | MNMD Definium Therapeutics, Inc. | Sale | 6,836 | $6.74 | $46.1K Sale | Form 4 ↗ |
| Mar 25, 2025 | Mark Sullivan Chief Legal Officer | MNMD Definium Therapeutics, Inc. | Sale | 6,576 | $6.74 | $44.3K Sale | Form 4 ↗ |
| Mar 25, 2025 | Carrie Liao Chief Accounting Officer | MNMD Definium Therapeutics, Inc. | Sale | 2,347 | $6.74 | $15.8K Sale | Form 4 ↗ |
| Dec 26, 2024 | Robert Barrow Chief Executive Officer, Director | MNMD Definium Therapeutics, Inc. | Sale | 19,106 | $7.43 | $142.0K Sale | Form 4 ↗ |
| Dec 26, 2024 | Carrie Liao Chief Accounting Officer | MNMD Definium Therapeutics, Inc. | Sale | 2,273 | $7.43 | $16.9K Sale | Form 4 ↗ |
| Dec 26, 2024 | Dan Karlin Chief Medical Officer | MNMD Definium Therapeutics, Inc. | Sale | 6,643 | $7.43 | $49.4K Sale | Form 4 ↗ |
| Dec 26, 2024 | Mark Sullivan Chief Legal Officer | MNMD Definium Therapeutics, Inc. | Sale | 4,519 | $7.43 | $33.6K Sale | Form 4 ↗ |
| Dec 5, 2024 | David W. Gryska Director | MNMD Definium Therapeutics, Inc. | Buy | 2,500 | $7.17 | $17.9K Buy | Form 4 ↗ |
32 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:16 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances